Often seen as an option of last resort for ventricular tachycardia, new research suggests catheter ablation could have a ...

Mount Sinai's AI-powered ECG tool now predicts individual risk for hypertrophic cardiomyopathy (HCM), enabling faster ...

Researchers have calibrated an AI algorithm to more specifically identify patients with hypertrophic cardiomyopathy (HCM), a ...

As Gov. Maura Healey embraced 5-year-old Lincoln, his mother sobbed and explained that the boy had just received a heart ...

Mount Sinai researchers studying a type of heart disease known as hypertrophic cardiomyopathy (HCM) have calibrated an ...

An Israeli study has identified TRIM63 as a significant genetic contributor to hypertrophic cardiomyopathy (HCM)—the most ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Tenaya Therapeutics (TNYA) announced interim data from its ongoing RIDGE natural history and seroprevalence study of adults with arrhythmogenic ...

Mount Sinai researchers studying a type of heart disease known as hypertrophic cardiomyopathy (HCM) have calibrated an artificial intelligence (AI) algorithm to quickly and more specifically identify ...

Barclays analyst Gena Wang initiated coverage of Cytokinetics (CYTK) with an Overweight rating and $55 price target The firm says the company ...

Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion ...